Atossa Therapeutics, Inc.
ATOSNASDAQHealthcareBiotechnology
Previous close
$2.54
−$0.05 · -1.93%
ATOS company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
47
Fair Value
Momentum
17
Strong Down
Sentiment
55
Mixed
Risk resilience
26
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteAtossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Steven C. Quay
- Listed since
- Nov 8, 2012
- Employees
- 16
Market position
Day range
Current $2.54
52-week range
Current $2.54
- Open
- $2.59
- Previous close
- $2.59
- Volume
- 25.66K
- 0.2× average
- Average volume
- 125.62K
- Average daily volume
- Market cap
- 25.34M USD
- Beta
- 1.25
- Market reference 1
- 50-day average
- $2.3034
- +10.27% above average
- 200-day average
- $6.0704
- -58.16% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 34.91M USD
- P/E (TTM)
- -0.59×
- P/B (TTM)
- 0.84×
- P/S (TTM)
- 0×
- EV / EBITDA
- -1×
- Earnings yield
- -45.62%
- Free cash flow yield
- -39.08%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -88.35%
- Return on assets
- -73.03%
- Return on invested capital
- -94.38%
Financial health
- Debt / equity
- 0×
- Current ratio
- 5.53×
- Altman Z-score
- -11.59
- Piotroski F-score
- 1 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 17K USD | 23K USD | 8K USD | 23K USD |
| Gross profit | — | −17K USD | −23K USD | −8K USD | −23K USD |
| Research and development | 21.19M USD | 14.12M USD | 17.33M USD | 15.08M USD | 9.21M USD |
| Selling, general, and administrative | 15.96M USD | 13.5M USD | 14.04M USD | 12.61M USD | 11.31M USD |
| Operating expenses | 37.14M USD | 27.62M USD | 31.38M USD | 27.69M USD | 20.52M USD |
| Interest income | 2.38M USD | 4.05M USD | 4.34M USD | 877K USD | 6K USD |
| Depreciation and amortization | 16K USD | 17K USD | 23K USD | 8K USD | 23K USD |
| Operating income | −37.14M USD | −27.62M USD | −31.38M USD | −27.69M USD | −20.52M USD |
| Net income | −34.77M USD | −25.5M USD | −30.09M USD | −26.96M USD | −20.61M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 27%
- 3 beats, 8 misses, 0 met estimates
- Average EPS surprise
- -403.44%
- 11 comparable reports
- Latest EPS result
- -0.95
- Estimate -1.02 · Beat by 6.86%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$42.50
1573.23% upsideRating distribution
5 ratingsRecent analyst actions
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Feb 2, 2026 | 1:15 | — | — |
Stock split | Apr 20, 2018 | 1:12 | — | — |
Stock split | Aug 26, 2016 | 1:15 | — | — |
Effective Feb 2, 2026
1:15
Effective Apr 20, 2018
1:12
Effective Aug 26, 2016
1:15
ATOS peers
ETFs holding ATOS
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 530.2K
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard Extended Market ETFVXF- Market value
- 205.08K
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Micro-Cap ETFIWC- Market value
- 76.63K
- Weight
- 0.01%
- AUM
- 1.53B USD
- Expense ratio
- 0.60%
- Price / 1D
- $198.39+1.10%
Continue in GoAI
Research ATOSresearch.disclaimer